Drugs / AD-2284
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06884098 | Mar → Apr 2025 overdue | hyperlipoproteinemia | Addpharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-2284 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06884098 ↗ |
| Route | Oral | “AD-2284, 1Tab., Per Oral” NCT06884098 ↗ |